Jobs boost for Kinsale as 300 construction jobs created
Published 27/02/2012 | 13:16
UP TO 300 construction jobs will be created during the expansion of a pharmaceutical plant in Cork, it was announced today.
Eli Lilly and Company, a global leader in biopharmaceuticals, revealed another 200 highly skilled employees will be needed after its €330 m investment in its facility in Kinsale.
Ed Canary, general manager of the Kinsale site, said the investment was an endorsement of its success in developing a biopharmaceutical business in recent years.
"This is in no small part due to the site's excellent performance record, the talent of the workforce, and the support from IDA Ireland," he said.
"In the past five years, we have hired and trained some highly talented people and now have a technical talent base and capability in biopharmaceutical commercialisation and manufacturing that makes us a very attractive company for highly skilled people."
The US firm already employs 700 people at four sites in Ireland.
Construction on the new 240,000-square-foot biopharmaceutical commercialisation and manufacturing facility will begin next month, with the site operational from late 2013.
Jobs Minister Richard Bruton said the Government's Action Plan for Jobs outlined a range of measures to target the high-end manufacturing and health/life sciences sectors for further growth and to deepen and develop the impact of multinational companies in Ireland.
"Today's announcement - that this world-leading company is making a substantial investment in expanding its facility in Kinsale with the creation of up to 200 permanent jobs - shows what is possible in these areas," he added.
"The Government is determined to ensure that more announcements like this become real in the coming years."
This is the second large investment Lilly has made in recent years at Kinsale, which manufacture active ingredients in treatments for illnesses such as cancer and diabetes.
Products are shipped from here to finishing plants around the world, where they are converted into tablets, capsules, or injectibles.
In 2006, the company announced a €300 m investment in its first biopharmaceutical manufacturing and new-product commercialisation facility at its Kinsale campus, which came on-stream in 2010.
Maria Crowe, president of global manufacturing operations for Lilly, commended the Irish government for its long-established pro-business environment and support of the pharmaceutical sector in Ireland through its science and technology policies.
"We in Lilly have seen this reflected in our deep and productive relationships with organisations such as the IDA and Irish academic institutions," she added.
"The output from this commitment to education is also reflected in the excellent candidates who apply to join our company, many of whom have gone on to careers at Lilly operations across the globe."